Abstract:Abstract Diffuse midline gliomas (DMG) are an aggressive and treatment-resistant form of brain cancer in urgent need of new and effective treatment strategies. Radiation therapy (RT) is the standard of care for DMGs, but these tumors often recur locally within the high-dose radiation field. Therefore, it is imperative to discover methods of overcoming RT resistance. DMGs are often characterized by the presence of driving mutation in the tail domain of histone H3 that converts the 27th residue from a lysine to a methionine (termed H3K27M). How the H2K27M mutation controls metabolism and RT resistance is not known. Using liquid chromatography/mass spectrometry metabolomics of irradiated and non-irradiated isogenic pairs, we found that patient-derived H3K27M-expressing cells (referred to as K27M cells going forward) possess altered metabolic profiles distinct from their K27M-KO counterparts, characterized by enrichment in metabolites associated with purine metabolism following RT treatment. Stable isotope tracing with precursors for de novo purine synthesis (15N-amide glutamine) and purine salvage (2H 2,8-hypoxanthine) showed that cells harboring the H3K27M mutation upregulate the de novo synthesis of guanylates but downregulate guanylate salvage. Consistent with these findings, pediatric high-grade glioma tumors and cell lines expressing K27M express lower levels of HPRT1/HGPRT, the rate-limiting enzyme in purine salvage. These findings suggest that K27M cells are preferentially reliant on de novo purine synthesis for guanylate production and that inhibition of this pathway might overcome RT resistance. Consistent with this hypothesis, we found that mycophenolic acid (MPA), a clinically available, blood-brain penetrant inhibitor of de novo purine synthesis, radiosensitized K27M neurospheres in vitro. Combination RT+MPA increased survival (38d post-implantation) over RT alone (31.5d post-implantation) in Rag1-KO mice bearing orthotopically implanted K27M tumors but did not cure tumors. To understand potential mechanisms of treatment resistance, we performed stable isotope tracing in irradiated K27M isogenic-paired cell lines. We found an H3K27M-specific, adaptive RT-mediated increase in guanylate salvage that was accompanied by increased HGPRT protein expression following RT. Additionally, we discovered that K27M xenograft tumors had high levels of the purine salvage substrate guanine. These findings suggest that K27M cells upregulate purine salvage to evade the effects of RT, which can confer resistance to inhibitors of de novo purine synthesis. Consistent with this hypothesis, H3K27M tumors in which HPRT1 was knocked down grew without difficulty but were profoundly sensitive to RT, which cured many tumors. These findings suggest that targeting the guanylate salvage pathway in DMG-K27M tumors may be a promising strategy to overcome treatment resistance. Citation Format: Erik R. Peterson, Peter Sajjakulnukit, Andrew Scott, Caleb Heaslip, Anthony Andren, Kari Wilder-Romans, Angelica Lin, Alexandra Obrien, Zitong Zhao, Li Zhang, Sriram Venneti, Carl Koschmann, Nada Jabado, Maria G. Castro, Daniel R. Wahl. Adaptive purine metabolism drives radiation therapy resistance in H3K27M-diffuse midline glioma [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1):Abstract nr B045.

Inhibition of H3K27M-enhanced ATM signaling increases radiation efficacy in diffuse midline glioma

ATM Inhibition Enhances the Efficacy of Radiation Across Distinct Molecular Subgroups of Pediatric High-Grade Glioma.

BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma

Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma

Adaptive rewiring of purine metabolism promotes treatment resistance in H3K27M-mutant diffuse midline glioma

Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer

Abstract B045: Adaptive purine metabolism drives radiation therapy resistance in H3K27M-diffuse midline glioma

Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma

Ctni-55. A Phase 0/1B Study Of Azd1390 Plus Radiotherapy In Newly Diagnosed, Mgmt-Unmethylated And Recurrent Glioblastoma Patients

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration

Abstract CT044: A phase 0/1b study of AZD1390 plus radiotherapy in newly-diagnosed, MGMT-unmethylated glioblastoma patients

Abstract 3305: WSD-0628, a novel brain penetrant ATM inhibitor, radiosensitizes GBM and melanoma patient derived xenografts

DNAR-06. LOSS OF HISTONE H3 THREONINE 45 PHOSPHORYLATION DECREASES H3K36ME3 TO ABROGATE THE RADIATION-INDUCED DNA DAMAGE IN GLIOBLASTOMA MULTIFORME

ATR inhibition radiosensitizes cells through augmented DNA Damage and G2 cell cycle arrest abrogation

DIPG-76. HISTONE H3 PHOSPHORYLATION IN H3K27M MIDLINE GLIOMAS

Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts

Activation of the phosphorylation of ATM contributes to radioresistance of glioma stem cells.